Intraovarian Administration of Autologous Menstrual Blood Derived-Mesenchymal Stromal Cells in Women with Premature Ovarian Failure.

Autor: Zafardoust S; Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Kazemnejad S; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran. Electronic address: s.kazemnejad@avicenna.ac.ir., Darzi M; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Fathi-Kazerooni M; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Saffarian Z; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Khalili N; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Edalatkhah H; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Mirzadegan E; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran., Khorasani S; Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Jazyk: angličtina
Zdroj: Archives of medical research [Arch Med Res] 2023 Feb; Vol. 54 (2), pp. 135-144. Date of Electronic Publication: 2023 Jan 25.
DOI: 10.1016/j.arcmed.2022.12.015
Abstrakt: Background: Premature ovarian failure (POF) is a well-known cause of infertility, particularly in women under the age of 40. POF is also associated with elevated gonadotropin levels, amenorrhea and sex-hormone deficiency.
Aim of the Study: In this study, the therapeutic potential of autologous mesenchymal stromal cells obtained from menstrual blood (Men-MSCs) for patients with POF was evaluated.
Methods: 15 POF patients were included in the study. The cultured Men-MSCs were confirmed by flow cytometry, karyotype, endotoxin and mycoplasma and were then injected into the patients' right ovary by vaginal ultrasound guidance and under general anesthesia and aseptic conditions. Changes in patients' anti-Müllerian hormone (AMH), antral follicle count (AFC), follicle-stimulating hormone (FSH), luteal hormone (LH), and estradiol (E2) levels, as well as general flushing and vaginal dryness were followed up to one year after treatment.
Results: All patients were satisfied with a decrease in general flushing and vaginal dryness. 4 patients (2.9%) showed a spontaneous return of menstruation without additional pharmacological treatment. There was a significant difference in AFC (0 vs. 1 ± 0.92 count, p value ≤0.001%), FSH (74 ± 22.9 vs. 54.8 ± 17.5 mIU/mL, p-value ≤0.05%), E2 (10.2 ± 6 vs. 21.8 ± 11.5 pg/mL p-value ≤0.01%), LH (74 ± 22.9 vs. 54.8 ± 17.5 IU/L,p-value ≤0.01%) during 3 months post-injection. However, there were no significant changes in AMH (p-value ≥0.05%). There were also no significant differences in assessed parameters between 3 and 6 months after cell injection.
Conclusion: According to the findings of this study, administration of Men-MSCs improved ovarian function and menstrual restoration in some POF patients.
Competing Interests: Conflicts of Interest None of the authors received grants or outside funding in support of this study. The authors have no conflict of interests.
(Copyright © 2023. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: